Standards of specialized diabetes care. Edited by Dedov I.I., Shestakova M.V., Mayorov A.Yu. 10th edition
Authors: Dedov Ivan I. , Shestakova Marina V. , Mayorov Alexander Yu. , Mokrysheva Natalya G. , Vikulova Olga K. , Galstyan Gagik R. , Kuraeva Tamara L. , Peterkova Valentina A. , Smirnova Olga M. , Starostina Elena G. , Surkova Elena V. , Sukhareva Olga Y. , Tokmakova Alla Y. , Shamkhalova Minara S. , Jarek-Martynova Ivona Renata , Artemova Ekaterina V. , Beshlieva Diana D. , Bondarenko Olga N. , Volevodz Natalya N. , Gomova Irina S. , Grigoryan Olga R. , Dzhemilova Zera N. , Esayan Roza M. , Ibragimova Liudmila I. , Kalashnikov Viktor Y. , Kononenko Irina V. , Laptev Dmitry N. , Lipatov Dmitry V. , Melnikova Olga G. , Mikhina Margarina S. , Michurova Marina S. , Motovilin Oleg G. , Nikonova Tatiana V. , Rozhivanov Roman V. , Sklyanik Igor A. , Shestakova Ekaterina A. 
Published: September 2022

Dear Colleagues!

We are glad to present the 10th Edition (revised) of the Standards of Specialized Diabetes Care. These evidence-based guidelines were designed to standardize and facilitate diabetes care in all regions of the Russian Federation.

The Standards are updated on the regular basis to incorporate new data and relevant recommendations from national and international clinical societies, including World Health Organization Guidelines (WHO, 2011, 2013), International Diabetes Federation (IDF, 2011, 2012, 2013), European Association for the Study of Diabetes (EASD 2018, 2019), American Diabetes Association (ADA, 2018, 2019, 2021), American Association of Clinical Endocrinologists (AACE, 2020, 2021), International Society for Pediatric and Adolescent Diabetes (ISPAD, 2018) and Russian Association of Endocrinologists (RAE, 2019). Current edition of the “Standards” also integrates results of completed randomized clinical trials (ADVANCE, ACCORD, VADT, UKPDS, SAVOR, TECOS, LEADER, EXAMINE, ELIXA, SUSTAIN, DEVOTE, EMPA-REG OUTCOME, CANVAS, DECLARE, CARMELINA, REWIND, CREDENCE, CAROLINA, DAPA-CKD, DAPA-HF, EMPEROR-Reduced trial, VERIFY, VERTIS CV, PIONEER, etc.), as well as findings from the national studies of diabetes mellitus (DM), conducted in close partnership with a number of Russian hospitals.

Latest data indicates that prevalence of DM in the world increased during the last decade more than two-fold, reaching some 537 million patients by the end of 2021. According to the current estimation by the International Diabetes Federation, 643 million patients will be suffering from DM by 2030 and 784 million by 2045.

Like many other countries, Russian Federation experiences a sharp rise in the prevalence of DM. According to Russian Federal Diabetes Register, there are at least 4 871 863 patients with DM in this country on 01.01.2021 (3,34% of population) with 92,3% (4 498 826)–Type 2 DM, 5,6% (271 468)–Type 1 DM and 2,1% (101 569)–other types of DM, including 9 729 women with gestational DM. However, these results underestimates real quantity of patients, because they consider only registered cases. Results of Russian epidemiological study (NATION) confirmed that only 54% of Type 2 DM are diagnosed. So real number of patients with DM in Russia is 10 million patients (about 7% of population). This is a great long-term problem, because a lot of patients are not diagnosed, so they don’t receive any treatment and have high risk of vascular complications.

Severe consequences of the global pandemic of DM include its vascular complications: nephropathy, retinopathy, coronary, cerebral and peripheral vascular disease. These conditions are responsible for the majority of cases of diabetes-related disability and death.

In сurrent edition of the “Standards”:

New goals of glycemic control for continuous glucose monitoring (time in range, below range and above range, glucose variability) are given.

It also features updated guidelines on stratification of treatment in newly diagnosed Type 2 diabetes.

In the recommendations for the personalization of the choice of antidiabetic agents, it is taken into account that in certain clinical situations (the presence of atherosclerotic cardiovascular diseases and their risk factors, chronic heart failure, chronic kidney disease, obesity, the risk of hypoglycemia) certain classes of hypoglycemic agents (or individual drugs) have proven advantages.

Indications for the use of antidiabetic agents in chronic kidney disease are expanded.

Information about insulin pump therapy is added.

Recommendations on vaccination are added.

An algorithm for replacing some insulin preparations with others is given.

This text represents a consensus by the absolute majority of national experts, achieved through a number of fruitful discussions held at national meetings and forums. These guidelines are intended for endocrinologists, primary care physicians, pediatricians and other medical professionals involved in the treatment of DM.

Compared with previous edition of the Standards of Specialized Diabetes Care edited by Dedov I.I., Shestakova M.V., ­Mayorov A.Yu., 10th edition, Moscow, 2021 (signed for printing on 10.09.2021) a number of changes have been made.

On behalf of the Working Group